Crosshair Therapeutics
Crosshair is leveraging a novel AI drug discovery platform to create an entirely new class of therapeutics to treat cancer, neurological disorders, aging, and other diseases. Their innovative D-Chain Technology enables precision targeting of difficult disease targets, including undruggable ones, through computational design and gene therapy vectors. The company aims to revolutionize disease treatment with personalized, targeted therapies that minimize side effects.
Industries
Nr. of Employees
small (1-50)
Crosshair Therapeutics
Products
Chain-like peptide therapeutics encoded for gene delivery
Small, flexible chain-like therapeutic molecules designed computationally and encoded as DNA for delivery by viral vectors to access hard-to-drug and intracellular targets.
Engineered viral delivery vectors for precision targeting
Custom-engineered adeno-associated virus vectors with modified surface properties to direct DNA-encoded payloads to specific cells or tumor-associated antigens, aiming to reduce systemic exposure and off-target effects.
Chain-like peptide therapeutics encoded for gene delivery
Small, flexible chain-like therapeutic molecules designed computationally and encoded as DNA for delivery by viral vectors to access hard-to-drug and intracellular targets.
Engineered viral delivery vectors for precision targeting
Custom-engineered adeno-associated virus vectors with modified surface properties to direct DNA-encoded payloads to specific cells or tumor-associated antigens, aiming to reduce systemic exposure and off-target effects.
Expertise Areas
- AI-driven drug discovery
- Gene therapy vector development
- Peptide-based therapeutic design
- Targeted delivery for oncology and neurological disorders
Key Technologies
- AI / computational modeling for therapeutic design
- Adeno-associated virus vector engineering
- DNA-encoded peptide therapeutics
- Surface engineering for targeted delivery